Stair Climbing, Endometriosis's Diabetes Toll, and Two Advances in Cancer Detection
Stair climbing cuts CV death risk 39%, endometriosis raises diabetes odds 46%, and two new tools advance early cancer detection.
By Dr. Asher Knippel
Five studies from the past week reveal new dimensions of everyday disease risk and bring two cancer-detection technologies closer to clinical use.
Friday, 14 August: Stair Climbing Linked to 39% Lower Risk of Cardiovascular Death
A meta-analysis of more than 480,000 adults, published in the American Journal of Cardiovascular Drugs by researchers at the University of East Anglia and Norfolk and Norwich University Hospital, finds that regular stair climbers are 39% less likely to die from cardiovascular disease and 24% less likely to die from any cause compared with those who rarely take the stairs.
The analysis pooled nine high-quality studies covering participants aged 35–84, with a median follow-up of 14 years and roughly equal representation between women and men. Both healthy adults and those with prior heart conditions were included. Regular stair climbers showed reduced rates of heart attack, stroke, and heart failure in addition to the mortality benefit.
The mechanism is well established: short, repeated bouts of moderate-intensity exertion strengthen cardiac muscle, lower resting blood pressure, and improve metabolic markers. What makes this finding notable is both its scale and the accessibility of the behaviour it highlights. Stair climbing requires no equipment, no cost, and no dedicated time block. For communities across Cyprus and the wider Mediterranean—where multi-storey apartment buildings coexist with walkable city centres—the message is direct: where there is a staircase, use it.
Wednesday, 12 August: Endometriosis Linked to 46% Higher Risk of Type 2 Diabetes
A retrospective cohort study of nearly three million women, published in Diabetologia by researchers at George Mason University, finds that women diagnosed with endometriosis have a 46% higher risk of developing type 2 diabetes compared with women without the condition.
The ARCHES study (Advancing Research on Cardiovascular Health and Endometriosis) drew on 25 years of medical records from the Utah Population Database—approximately 100,000 of the three million women had a confirmed endometriosis diagnosis. The association was strongest before menopause (55% higher risk in premenopausal women) and persisted even among women with a body mass index below 30, suggesting the link is not simply driven by obesity. Researchers hypothesise that the chronic systemic inflammation characteristic of endometriosis may disrupt insulin signalling over time.
Endometriosis affects roughly one in ten women of reproductive age. It is already associated with elevated cardiovascular risk and chronic pelvic pain; this study suggests its metabolic toll may extend to diabetes. If confirmed by mechanistic research, the finding could prompt earlier cardiometabolic screening for women with the condition, regardless of their weight. The results are not yet sufficient to change clinical guidelines, but the signal from three million records warrants close attention.
Wednesday, 12 August: Estrogen-Only Hormone Therapy Associated with Fewer Alzheimer's Brain Hallmarks
An autopsy study published in Neurology by researchers at Stanford Medicine finds that women who received estrogen-only menopausal hormone therapy had 35% fewer Alzheimer's-related pathological changes in their brain tissue at post-mortem examination and 39% lower odds of a clinical dementia diagnosis during their lifetimes, compared with women who did not use hormone therapy.
The pathological endpoint—examining brain tissue directly for amyloid plaques and tau tangles, the microscopic hallmarks of Alzheimer's disease—provides stronger evidence than clinical diagnosis alone. A study participant could have substantial Alzheimer's pathology without yet meeting the clinical threshold for dementia; this approach looks for biological effect rather than symptom expression.
Several caveats apply. This is an observational study, not a randomised controlled trial. Women who chose hormone therapy may differ systematically from those who did not in ways the analysis could not fully adjust for. Therapy began at an average age of 70, well past the early postmenopausal period identified by the "critical window hypothesis" as the optimal time for estrogen's potential neuroprotective effect. These results do not establish that estrogen prevents Alzheimer's disease, and no reader should alter a hormone therapy regimen without consulting a clinician. They do, however, strengthen the case for well-powered randomised trials to resolve the question definitively.
Sunday, 10 August: UCLA Develops MethylScan—a Low-Cost Blood Test for Four Cancer Types
Researchers at UCLA have developed a blood test called MethylScan that detects liver, lung, ovarian, and stomach cancers—as well as several non-cancerous conditions including liver disease—from a single blood draw. The method was described in the Proceedings of the National Academy of Sciences.
MethylScan examines DNA methylation patterns in cell-free DNA circulating in the bloodstream. Methylation refers to chemical tags attached to DNA that regulate which genes are active; these patterns differ by tissue type and shift in characteristic ways when cells become cancerous. By reading these signatures, the test can identify not only whether cancer is likely present but where in the body it likely originated.
In initial testing, MethylScan detected approximately 63% of cancers across all stages and around 55% of early-stage cancers—the stage at which most solid tumours are most treatable. The UCLA team emphasise that cost is central to the design: a clinically accurate but expensive test will not reduce population-level cancer mortality in communities with limited healthcare access. The technology remains early-stage; validation in large, prospective trials is necessary before clinical adoption. It represents, however, a methodologically distinct approach from existing multi-cancer screening tests, which typically search for somatic mutations rather than methylation signatures.
Wednesday, 12 August: Ultra-Processed Foods Linked to 29% Higher Prostate Cancer Risk
A study published in The American Journal of Medicine, drawing on nationally representative data from 17,024 U.S. men who participated in the National Health and Nutrition Examination Survey between 2003 and 2023, finds that men in the three highest ultra-processed food consumption groups had a 29% higher risk of prostate cancer compared with those in the lowest-intake group.
Ultra-processed foods are defined here as industrially manufactured products characterised by long ingredient lists, artificial additives, and substantial reformulation from their whole-food origins—packaged snacks, reconstituted meat products, carbonated soft drinks, and mass-produced bread and pastries. Participants in the highest-intake group derived more than 44% of their daily calories from such products.
Prostate cancer is the most common non-skin cancer in men globally. The study cannot establish causation: dietary habits, healthcare access, and cancer screening rates interact in ways a survey-based design cannot disentangle. However, the finding adds to a consistent body of evidence linking heavy ultra-processed food consumption to chronic disease risk. The Mediterranean diet—centred on olive oil, legumes, fish, vegetables, and minimally processed whole grains—stands in structural contrast to the dietary pattern flagged here, and represents an evidence-supported alternative that is widely accessible across Cyprus and the eastern Mediterranean.
This article is a journalistic summary of recent health and medicine developments compiled for general information purposes. It does not constitute medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health plan.